Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs Boston Beer Company Inc (SAM) Price & Performance

CVS Health CorpTrade
Boston Beer Company IncTrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs Boston Beer Company Inc — how do they compare? CVS Health Corp trades at $93.49 (market cap $122.36B), while Boston Beer Company Inc trades at $179.73 (market cap $1.86B). The key difference: CVS Health Corp is far larger — about 65.8× Boston Beer Company Inc's market cap, and CVS Health Corp pays a 2.78% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.

CVSSAM
Market Cap
$122.36B$1.86B
Sector
HealthConsumer Staples
52-Week High
$110.60$260.05
52-Week Low
$64.88$161.08
Enterprise Value
$184.71B$1.63B
Dividend Yield
2.78%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.

Boston Beer Company Inc

The Boston Beer Company (SAM) trades at $186.61, up 1.94% on the day, with a bullish technical signal driven by moving averages. The stock shows mixed fundamentals; while the P/E ratio of 22.66 and P/S of 0.99 suggest reasonable valuation, recent quarterly earnings have missed expectations, and the company faces volume declines in core brands. Positive cash flow and innovation in ready-to-drink products provide some offset. Analyst sentiment is cautious, with a consensus price target of $207.33 but a majority hold rating.

Outlook: Upside exists if new product growth accelerates and margins improve, but risks from weak demand and competitive pressure persist. The stock's trajectory hinges on reversing volume trends and achieving future earnings targets, making it a hold for now with watchful optimism.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS

About Boston Beer Company Inc

Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.

Read more on SAM